Gilead Sciences and Arcus Biosciences Expand Partnership
Tuesday, May 16, 2023
Gilead Sciences and Arcus Biosciences announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases.
Under the terms of the expanded collaboration, Arcus will receive an upfront payment of $35 million and will initiate research programmes against up to four targets jointly selected by the parties that are applicable to inflammatory diseases.
Gilead is committed to accessing innovative approaches to address the significant unmet medical needs across a range of inflammatory conditions, and this expanded collaboration with Arcus underscores that commitment. Arcus is an excellent partner with clear strengths in discovery and development, and it is believed that this partnership will significantly accelerate the progress in developing transformative new therapies for inflammatory diseases.
The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into inflammation.
